Skip to main content
      US Electronic Health Record cohort 2000+pts

      Incidence Heart Failure over 10 yrs 6.8%

      HF asso w/
      Older
      Male
      Lower eGFR

      Aurelie Najm AurelieRheumo

      4 months 1 week ago
      US Electronic Health Record cohort 2000+pts Incidence Heart Failure over 10 yrs 6.8% HF asso w/ Older Male Lower eGFR Hypertensive medication Diabetes TTMTS MTX, TNFi Higher CRP Probably surrogates for High Disease Activity... How do we detect it? Maybe not by using the https://t.co/s9SjEyk3WF
      @RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is no

      David Liew drdavidliew

      4 months 1 week ago
      @RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4
      @RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with

      David Liew drdavidliew

      4 months 1 week ago
      @RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile #ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB
      Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card.

      We’re not exa

      David Liew drdavidliew

      4 months 1 week ago
      Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card. We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better. #ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW
      Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI s

      Richard Conway RichardPAConway

      4 months 1 week ago
      Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa
      IgG4 - Rare but Rx

      Several studies #ACR25 @ACRheum were presented
      Outcome measures

      Rx
      #steroids

      #CD19 mAb #Inebiliz

      Janet Pope Janetbirdope

      4 months 1 week ago
      IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk
      Sjögren’s, decoded by Ab -->ESSDAI domains:
      • anti-SSA → glandular
      • anti-Ro52 / SCL70 → biologic activity

      Jiha Lee JihaRheum

      4 months 1 week ago
      Sjögren’s, decoded by Ab -->ESSDAI domains: • anti-SSA → glandular • anti-Ro52 / SCL70 → biologic activity • anti-nucleosome → pulmonary • anti-histone → pulmonary + cutaneous Distinct serologic–ESSDAI patterns may guide monitoring and management @RheumNow #ACR25 A#2295
      #ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY show

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago

      #ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D

      In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% s

      Antoni Chan MD (Prof) synovialjoints

      4 months 1 week ago
      In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% sensitivity and 0.861 AUC. Supports biomarker-driven personalization of PsA treatment. Abstract#2371 @RheumNow #ACR25 https://t.co/lojQFfWsJi
      Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #

      Richard Conway RichardPAConway

      4 months 1 week ago
      Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX
      In RA, “strong bones” can give false reassurance.
      Pts with higher baseline BMD had faster bone loss, often tied to G

      Jiha Lee JihaRheum

      4 months 1 week ago
      In RA, “strong bones” can give false reassurance. Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline. @RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9
      After melanoma, should RA patients stop DMARDs?

      These VA data (n=644) showed no mortality signal, and trending to survi

      David Liew drdavidliew

      4 months 1 week ago
      After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln
      #ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) i

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too! Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF
      ×